(Q57793035)

1

0 references

A. C. Wiseman

2

0 references

K. McCague

4

0 references

Y. Kim

5

0 references

F. Geissler

6

0 references

B. Nashan

Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.

7

0 references

publication date

6 September 2013

0 references

published in

Clinical Transplantation

0 references

volume

27

0 references

issue

6

0 references

page(s)

E625-E635

0 references

cites work

1 reference

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo

21 January 2018

1 reference

Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus

21 January 2018

1 reference

Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.

21 January 2018

1 reference

A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis

21 January 2018

1 reference

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial

21 January 2018

1 reference

Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor

21 January 2018

1 reference

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

21 January 2018

1 reference

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature

21 January 2018

1 reference

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

21 January 2018

1 reference

Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing

21 January 2018

1 reference

Persistent effects of everolimus on strength of experimental wounds in intestine and fascia.

21 January 2018

1 reference

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

21 January 2018

1 reference

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

21 January 2018

1 reference

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

21 January 2018

1 reference

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study

21 January 2018

1 reference

The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

21 January 2018

1 reference

Are wound complications after a kidney transplant more common with modern immunosuppression?

21 January 2018

1 reference

Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients

21 January 2018

1 reference

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

21 January 2018

1 reference

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

21 January 2018

1 reference

Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine

21 January 2018

1 reference

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administration

21 January 2018

1 reference